Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease

  • Technology appraisal guidance
  • TA20
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1

Riluzole is recommended for the treatment of individuals with the amyotrophic lateral sclerosis (ALS) form of motor neurone disease (MND).

1.2

Riluzole therapy should be initiated by a neurological specialist with expertise in the management of MND. Routine supervision of therapy should be managed by locally agreed shared care protocols undertaken by general practitioners.